Earnings summaries and quarterly performance for Tango Therapeutics.
Executive leadership at Tango Therapeutics.
Board of directors at Tango Therapeutics.
Research analysts covering Tango Therapeutics.
Recent press releases and 8-K filings for TNGX.
Tango Therapeutics Announces CEO Transition and 2026 Clinical Milestones
TNGX
CEO Change
New Projects/Investments
Guidance Update
- Malte Peters has been appointed CEO of Tango Therapeutics, succeeding Barbara Weber, effective last Thursday (prior to January 14, 2026). Peters, who has served on the board since 2018, will focus on advancing the company into late-phase drug development and regulatory activities.
- The company is well-capitalized with a cash runway into 2028.
- Key clinical milestones for 2026 include launching a pivotal trial in second-line pancreatic cancer for TNG462, completing TNG462 RAS inhibitor combination studies, and initiating Phase 1 clinical trials for TNG961.
- TNG462 monotherapy has shown a 27% response rate and 6.4 months median progression-free survival across multiple tumor histologies, and 7.2 months median PFS in pancreatic cancer, doubling the standard of care. The combination study of TNG462 with RAS inhibitors is in dose escalation, with 30 patients dosed to date and early signs of clinical activity.
Jan 14, 2026, 5:45 PM
Tango Therapeutics Provides 2025 Achievements and Outlines 2026 Strategic Execution
TNGX
Equity Raise
New Projects/Investments
Guidance Update
- Tango Therapeutics reported a cash balance of $343 million as of December 31, 2025, following a $225 million equity raise, providing a cash runway into 2028.
- The company achieved significant clinical progress in 2025, including FDA support for a pivotal study design for Vopimetostat in 2L MTAP-del pancreatic cancer and the initiation of a combination study with RAS(ON) inhibitors.
- Vopimetostat monotherapy demonstrated an Overall Response Rate (ORR) of 27% and a median Progression-Free Survival (mPFS) of 6.4 months across various histologies, with early encouraging efficacy data from its combination study with RAS(ON) inhibitors.
- Key milestones for 2026 include the planned launch of the Vopimetostat pivotal study in 2L pancreatic cancer, data updates for Vopimetostat in lung cancer and its RAS inhibitor combination, and data for TNG456.
- The pipeline also features TNG456, a brain-penetrant PRMT5 inhibitor in Phase 1/2 for glioblastoma with FDA Fast Track and Orphan Drug Designation, and TNG961, an HBS1L degrader, which is IND-ready for Phase 1 in 2026.
Jan 14, 2026, 5:45 PM
Tango Therapeutics Appoints New CEO and Outlines 2026 Clinical Milestones
TNGX
CEO Change
New Projects/Investments
Guidance Update
- Malte Peters has been appointed as the new Chief Executive Officer of Tango Therapeutics, succeeding Barbara Weber, who is now Executive Chairman.
- The company is well-capitalized with a cash runway into 2028.
- Key milestones for 2026 include launching a second-line pivotal trial in pancreatic cancer, completing TNG462 RAS inhibitor combination studies, and evaluating TNG456 efficacy in glioblastoma.
- Clinical data for TNG462 monotherapy shows a 27% response rate and 6.4 months median progression-free survival in 94 patients across various tumor histologies. The combination study of TNG462 with RAS inhibitors has dosed 30 patients and shows early signs of clinical activity.
- Tango's pipeline also includes TNG908, a brain-penetrant PRMT5 inhibitor, which has dosed its first glioblastoma patients in a Phase 1-2 trial, and TNG961, an HBS1L degrader, ready to start clinical trials this year.
Jan 14, 2026, 5:45 PM
Tango Therapeutics Announces CEO Transition and 2026 Clinical Milestones
TNGX
CEO Change
New Projects/Investments
Guidance Update
- Tango Therapeutics announced a CEO transition, with Malte Peters taking over from Barbara Weber as of last Thursday.
- The company is well capitalized with a cash runway into 2028.
- Key milestones for 2026 include launching a second-line pivotal trial in pancreatic cancer for TNG462, completing TNG462 RAS inhibitor combination studies, and initiating Phase 1 clinical trials for the HBS1L degrader, TNG961.
- TNG462 monotherapy has demonstrated a 27% response rate and 6.4 months median progression-free survival across multiple tumor histologies, and a 25% response rate with 7.2 months median PFS in pancreatic cancer, which is double the standard of care.
- The combination study of TNG462 with Revolution Medicines' RAS inhibitors is in dose escalation with 30 patients dosed, showing good tolerability and early signs of clinical activity.
Jan 14, 2026, 5:45 PM
Tango Therapeutics Reports Strong Financial Position and Clinical Pipeline Progress
TNGX
New Projects/Investments
Guidance Update
- Tango Therapeutics reported a cash balance of $343 million as of December 31, 2025, providing a cash runway into 2028, following a $225 million equity raise.
- The company plans to initiate a pivotal study for vopimetostat (TNG462) in 2L MTAP-del pancreatic cancer in 2026, with FDA support for the study design. Clinical data shows a median progression-free survival (mPFS) of 7.2 months and an overall response rate (ORR) of 25% in this patient group.
- Vopimetostat demonstrated robust activity across various MTAP-del cancers, achieving an overall ORR of 27% and an ORR of 49% with mPFS of 9.1 months in a histology-selective cohort.
- The pipeline also includes TNG456, a brain-penetrant PRMT5 inhibitor in phase 1/2 development for MTAP-del glioblastoma with FDA Fast Track and Orphan Drug Designation, and TNG961, which is IND-ready and expected to enter Phase 1 in 2026.
Jan 14, 2026, 12:00 PM
Tango Therapeutics Announces CEO Transition and New Appointment
TNGX
CEO Change
Management Change
Executive Compensation
- Dr. Barbara Weber retired as CEO of Tango Therapeutics, Inc. on January 8, 2026, and will transition to Executive Chair for 2026.
- Dr. Malte Peters was appointed President and Chief Executive Officer, effective January 8, 2026, with an annual base salary of $720,000 and a target cash bonus opportunity of 60% of his base salary. He was also granted an option to purchase 1,650,000 shares and 350,000 restricted stock units.
- As of December 31, 2025, the company reported $343 million in cash, cash equivalents, and marketable securities.
- Tango Therapeutics renewed its guidance for 2026 clinical milestones, including initial safety and efficacy data for combination trials and the start of a pivotal study for vopimetostat monotherapy in 2L pancreatic cancer.
Jan 8, 2026, 2:10 PM
Tango Therapeutics Announces CEO Transition
TNGX
CEO Change
Management Change
Guidance Update
- Tango Therapeutics (NASDAQ: TNGX) announced a leadership transition, with founding CEO Dr. Barbara Weber retiring, effective January 8, 2026.
- Dr. Weber will transition to Executive Chair for 2026 and then serve as non-executive chair starting in 2027.
- Dr. Malte Peters, a current board member, has been appointed President and Chief Executive Officer, effective immediately.
- The company also renewed its guidance on anticipated clinical milestones for 2026, which include initial safety and efficacy data for combination trials and TNG456 monotherapy, a lung cancer update for vopimetostat monotherapy, and the start of a pivotal study for vopimetostat monotherapy in 2L pancreatic cancer.
Jan 8, 2026, 2:05 PM
Tango Therapeutics Provides Clinical Program Updates and Strategic Outlook
TNGX
New Projects/Investments
- Tango Therapeutics (TNGX), a precision oncology company, is focused on novel targets with three clinical programs heading into 2026.
- Their lead program, bopametastat, an MTA cooperative PRMT5 inhibitor, demonstrated an overall response rate of 27% and median PFS of 6.4 months across over 150 patients. In second-line pancreatic cancer, it achieved an ORR of 25% and median PFS of 7.2 months, significantly surpassing the standard of care.
- Tango plans to initiate a pivotal Phase 3 study for bopametastat in second-line pancreatic cancer in 2026, following FDA alignment on the approximately 300-patient trial design.
- The company is also developing TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma, with data expected in 2026.
- Tango Therapeutics' cash runway extends into 2028, sufficient to cover the first pivotal study and ongoing clinical activities.
Dec 3, 2025, 6:30 PM
Tango Therapeutics Details Bopametastat Clinical Progress and Pivotal Study Plans
TNGX
New Projects/Investments
- Tango Therapeutics (TNGX) presented positive clinical data for bopametastat (formerly TNG462), an MTA cooperative PRMT5 inhibitor, including an overall response rate of 27% and a median PFS of 6.4 months across over 150 patients. In second-line pancreatic cancer, bopametastat achieved a 25% overall response rate and a median PFS of 7.2 months, significantly outperforming standard of care chemotherapy.
- The company has received FDA alignment for the design of a pivotal Phase 3 study for bopametastat in second-line pancreatic cancer, which is slated to begin in 2026. This approximately 300-patient trial will compare bopametastat to standard of care chemotherapy.
- TNGX is also advancing TNG456, a brain-penetrant PRMT5 inhibitor for glioblastoma (GBM), with data anticipated in 2026, and TNG260, which demonstrated early proof of concept in STK11 mutant and KRAS wild type non-small cell lung cancer.
- The company reports a cash runway extending into 2028, sufficient to cover the first pivotal study and all ongoing clinical trial activities.
Dec 3, 2025, 6:30 PM
Tango Therapeutics Updates on Vopimetostat Progress and Extends Cash Runway
TNGX
New Projects/Investments
Guidance Update
- Tango Therapeutics' lead program, vopimetostat, demonstrated an Overall Response Rate (ORR) of 25% and a median Progression-Free Survival (PFS) of 7.2 months in second-line MTAP-deleted pancreatic cancer.
- The company has secured FDA buy-in for the design of its 300-patient pivotal study for second-line pancreatic cancer, which will use a hierarchical design for PFS and OS readouts.
- Combination studies of vopimetostat with RAS inhibitors are enrolling rapidly, with a data update anticipated in 2026; the target ORR for convincing efficacy in pancreatic cancer is 45-50%.
- Tango Therapeutics has extended its cash runway into 2028 following a recent raise of $225 million (net proceeds of $212 million), which is expected to fund current enabling studies and the second-line pivotal study.
Nov 19, 2025, 4:30 PM
Fintool News
In-depth analysis and coverage of Tango Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more